📊 LTRN Key Takeaways
Is Lantern Pharma Inc. (LTRN) a Good Investment?
Lantern Pharma is a pre-revenue biotech company with severe financial distress, burning $15.7M annually while holding only $4.4M in cash, implying a ~3.5-month runway. Despite marginal year-over-year improvement in net losses, the company lacks revenue generation, has a microscopic balance sheet ($11M assets), and faces imminent capital needs that will likely trigger significant shareholder dilution.
Lantern Pharma is pre-revenue with persistent operating and net losses; a ~$15.7M annual operating cash burn against $4.4M in cash implies a short runway and a high likelihood of near-term, dilutive financing. While liabilities are low, debt is absent, and YoY loss metrics improved, fundamentals remain weak until sustainable revenue or sizable non-dilutive funding is secured.
Why Buy Lantern Pharma Inc. Stock? LTRN Key Strengths
- Net loss improving 17.6% year-over-year showing operational cost discipline
- Zero debt obligation eliminates financial leverage risk and interest burden
- Current ratio of 2.40x and quick ratio of 2.40x indicate adequate short-term liquidity on balance sheet
- Debt-free balance sheet (D/E 0.00x)
- Solid near-term liquidity (current ratio 2.40x)
- Improving net loss/EPS YoY with minimal capex
LTRN Stock Risks: Lantern Pharma Inc. Investment Risks
- Pre-revenue company with zero income-generating operations and undefined path to monetization
- Operating cash burn of $15.7M annually against $4.4M cash reserves indicates critical runway of ~3.5 months without capital raise
- Extremely thin equity base of $6.5M and total assets of $11M provide minimal financial cushion for R&D or operational setbacks
- High probability of dilutive capital raise or debt financing in near term to avoid insolvency
- Pharmaceutical development carries inherent pipeline risk with potential for clinical failures
- Limited cash runway vs. burn (−$15.68M OCF vs $4.42M cash)
- No revenue; continued operating losses and execution risk
- High dilution/going-concern risk due to likely capital raises
Key Metrics to Watch
- Monthly cash burn rate and projected runway to profitability or funding need
- Clinical trial progress and any regulatory milestone announcements
- Capital raise announcements and dilution impact on existing shareholders
- Operating expense trends and burn rate trajectory
- Operating cash flow (quarterly burn)
- Cash & equivalents (runway)
Lantern Pharma Inc. (LTRN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.40x current ratio provides a solid financial cushion.
LTRN Profit Margin, ROE & Profitability Analysis
LTRN vs Healthcare Sector: How Lantern Pharma Inc. Compares
How Lantern Pharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lantern Pharma Inc. Stock Overvalued? LTRN Valuation Analysis 2026
Based on fundamental analysis, Lantern Pharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lantern Pharma Inc. Balance Sheet: LTRN Debt, Cash & Liquidity
LTRN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lantern Pharma Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.93 indicates the company is currently unprofitable.
LTRN Revenue Growth, EPS Growth & YoY Performance
Lantern Pharma Inc. Dividends, Buybacks & Capital Allocation
LTRN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lantern Pharma Inc. (CIK: 0001763950)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LTRN
What is the AI rating for LTRN?
Lantern Pharma Inc. (LTRN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LTRN's key strengths?
Claude: Net loss improving 17.6% year-over-year showing operational cost discipline. Zero debt obligation eliminates financial leverage risk and interest burden. ChatGPT: Debt-free balance sheet (D/E 0.00x). Solid near-term liquidity (current ratio 2.40x).
What are the risks of investing in LTRN?
Claude: Pre-revenue company with zero income-generating operations and undefined path to monetization. Operating cash burn of $15.7M annually against $4.4M cash reserves indicates critical runway of ~3.5 months without capital raise. ChatGPT: Limited cash runway vs. burn (−$15.68M OCF vs $4.42M cash). No revenue; continued operating losses and execution risk.
What is LTRN's revenue and growth?
Lantern Pharma Inc. reported revenue of N/A.
Does LTRN pay dividends?
Lantern Pharma Inc. does not currently pay dividends.
Where can I find LTRN SEC filings?
Official SEC filings for Lantern Pharma Inc. (CIK: 0001763950) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LTRN's EPS?
Lantern Pharma Inc. has a diluted EPS of $-1.57.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LTRN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lantern Pharma Inc. has a STRONG SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LTRN stock overvalued or undervalued?
Valuation metrics for LTRN: ROE of -262.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LTRN stock in 2026?
Our dual AI analysis gives Lantern Pharma Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LTRN's free cash flow?
Lantern Pharma Inc.'s operating cash flow is $-15.7M, with capital expenditures of $1.7K.
How does LTRN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -262.0% (avg: 15%), current ratio 2.40 (avg: 2).